Search

Your search keyword '"Roobol, Monique J."' showing total 1,943 results
Start Over Author "Roobol, Monique J."
1,943 results on '"Roobol, Monique J."'

1. Follow-up on patients with initial negative mpMRI target and systematic biopsy for PI-RADS ≥ 3 lesions – an EAU-YAU study enhancing prostate cancer detection

Author

Zattoni, Fabio, Gandaglia, Giorgio, van den Bergh, Roderick C. N., Marra, Giancarlo, Valerio, Massimo, Martini, Alberto, Olivier, Jonathan, Puche – SanzI, Ignacio, Rajwa, Pawel, Maggi, Martina, Campi, Riccardo, Nicoletti, Rossella, Amparore, Daniele, De Cillis, Sabrina, Zhuang, Junlong, Guo, Hongqian, Fuschi, Andrea, Veccia, Alessandro, Ditonno, Francesco, Paulino Pereira, Leonor J., Marquis, Alessandro, Barletta, Francesco, Leni, Riccardo, Kasivisvanathan, Veeru, Antonelli, Alessandro, Rivas, Juan Gomez, Remmers, Sebastiaan, Roobol, Monique J., Briganti, Alberto, Dal Moro, Fabrizio, and Novara, Giacomo

Published
2024
Full Text
View/download PDF

3. Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants

Author

Wang, Anqi, Shen, Jiayi, Rodriguez, Alex A., Saunders, Edward J., Chen, Fei, Janivara, Rohini, Darst, Burcu F., Sheng, Xin, Xu, Yili, Chou, Alisha J., Benlloch, Sara, Dadaev, Tokhir, Brook, Mark N., Plym, Anna, Sahimi, Ali, Hoffman, Thomas J., Takahashi, Atushi, Matsuda, Koichi, Momozawa, Yukihide, Fujita, Masashi, Laisk, Triin, Figuerêdo, Jéssica, Muir, Kenneth, Ito, Shuji, Liu, Xiaoxi, Uchio, Yuji, Kubo, Michiaki, Kamatani, Yoichiro, Lophatananon, Artitaya, Wan, Peggy, Andrews, Caroline, Lori, Adriana, Choudhury, Parichoy P., Schleutker, Johanna, Tammela, Teuvo L. J., Sipeky, Csilla, Auvinen, Anssi, Giles, Graham G., Southey, Melissa C., MacInnis, Robert J., Cybulski, Cezary, Wokolorczyk, Dominika, Lubinski, Jan, Rentsch, Christopher T., Cho, Kelly, Mcmahon, Benjamin H., Neal, David E., Donovan, Jenny L., Hamdy, Freddie C., Martin, Richard M., Nordestgaard, Borge G., Nielsen, Sune F., Weischer, Maren, Bojesen, Stig E., Røder, Andreas, Stroomberg, Hein V., Batra, Jyotsna, Chambers, Suzanne, Horvath, Lisa, Clements, Judith A., Tilly, Wayne, Risbridger, Gail P., Gronberg, Henrik, Aly, Markus, Szulkin, Robert, Eklund, Martin, Nordstrom, Tobias, Pashayan, Nora, Dunning, Alison M., Ghoussaini, Maya, Travis, Ruth C., Key, Tim J., Riboli, Elio, Park, Jong Y., Sellers, Thomas A., Lin, Hui-Yi, Albanes, Demetrius, Weinstein, Stephanie, Cook, Michael B., Mucci, Lorelei A., Giovannucci, Edward, Lindstrom, Sara, Kraft, Peter, Hunter, David J., Penney, Kathryn L., Turman, Constance, Tangen, Catherine M., Goodman, Phyllis J., Thompson, Jr., Ian M., Hamilton, Robert J., Fleshner, Neil E., Finelli, Antonio, Parent, Marie-Élise, Stanford, Janet L., Ostrander, Elaine A., Koutros, Stella, Beane Freeman, Laura E., Stampfer, Meir, Wolk, Alicja, Håkansson, Niclas, Andriole, Gerald L., Hoover, Robert N., Machiela, Mitchell J., Sørensen, Karina Dalsgaard, Borre, Michael, Blot, William J., Zheng, Wei, Yeboah, Edward D., Mensah, James E., Lu, Yong-Jie, Zhang, Hong-Wei, Feng, Ninghan, Mao, Xueying, Wu, Yudong, Zhao, Shan-Chao, Sun, Zan, Thibodeau, Stephen N., McDonnell, Shannon K., Schaid, Daniel J., West, Catharine M. L., Barnett, Gill, Maier, Christiane, Schnoeller, Thomas, Luedeke, Manuel, Kibel, Adam S., Drake, Bettina F., Cussenot, Olivier, Cancel-Tassin, Geraldine, Menegaux, Florence, Truong, Thérèse, Koudou, Yves Akoli, John, Esther M., Grindedal, Eli Marie, Maehle, Lovise, Khaw, Kay-Tee, Ingles, Sue A., Stern, Mariana C., Vega, Ana, Gómez-Caamaño, Antonio, Fachal, Laura, Rosenstein, Barry S., Kerns, Sarah L., Ostrer, Harry, Teixeira, Manuel R., Paulo, Paula, Brandão, Andreia, Watya, Stephen, Lubwama, Alexander, Bensen, Jeannette T., Butler, Ebonee N., Mohler, James L., Taylor, Jack A., Kogevinas, Manolis, Dierssen-Sotos, Trinidad, Castaño-Vinyals, Gemma, Cannon-Albright, Lisa, Teerlink, Craig C., Huff, Chad D., Pilie, Patrick, Yu, Yao, Bohlender, Ryan J., Gu, Jian, Strom, Sara S., Multigner, Luc, Blanchet, Pascal, Brureau, Laurent, Kaneva, Radka, Slavov, Chavdar, Mitev, Vanio, Leach, Robin J., Brenner, Hermann, Chen, Xuechen, Holleczek, Bernd, Schöttker, Ben, Klein, Eric A., Hsing, Ann W., Kittles, Rick A., Murphy, Adam B., Logothetis, Christopher J., Kim, Jeri, Neuhausen, Susan L., Steele, Linda, Ding, Yuan Chun, Isaacs, William B., Nemesure, Barbara, Hennis, Anselm J. M., Carpten, John, Pandha, Hardev, Michael, Agnieszka, De Ruyck, Kim, De Meerleer, Gert, Ost, Piet, Xu, Jianfeng, Razack, Azad, Lim, Jasmine, Teo, Soo-Hwang, Newcomb, Lisa F., Lin, Daniel W., Fowke, Jay H., Neslund-Dudas, Christine M., Rybicki, Benjamin A., Gamulin, Marija, Lessel, Davor, Kulis, Tomislav, Usmani, Nawaid, Abraham, Aswin, Singhal, Sandeep, Parliament, Matthew, Claessens, Frank, Joniau, Steven, Van den Broeck, Thomas, Gago-Dominguez, Manuela, Castelao, Jose Esteban, Martinez, Maria Elena, Larkin, Samantha, Townsend, Paul A., Aukim-Hastie, Claire, Bush, William S., Aldrich, Melinda C., Crawford, Dana C., Srivastava, Shiv, Cullen, Jennifer, Petrovics, Gyorgy, Casey, Graham, Wang, Ying, Tettey, Yao, Lachance, Joseph, Tang, Wei, Biritwum, Richard B., Adjei, Andrew A., Tay, Evelyn, Truelove, Ann, Niwa, Shelley, Yamoah, Kosj, Govindasami, Koveela, Chokkalingam, Anand P., Keaton, Jacob M., Hellwege, Jacklyn N., Clark, Peter E., Jalloh, Mohamed, Gueye, Serigne M., Niang, Lamine, Ogunbiyi, Olufemi, Shittu, Olayiwola, Amodu, Olukemi, Adebiyi, Akindele O., Aisuodionoe-Shadrach, Oseremen I., Ajibola, Hafees O., Jamda, Mustapha A., Oluwole, Olabode P., Nwegbu, Maxwell, Adusei, Ben, Mante, Sunny, Darkwa-Abrahams, Afua, Diop, Halimatou, Gundell, Susan M., Roobol, Monique J., Jenster, Guido, van Schaik, Ron H. N., Hu, Jennifer J., Sanderson, Maureen, Kachuri, Linda, Varma, Rohit, McKean-Cowdin, Roberta, Torres, Mina, Preuss, Michael H., Loos, Ruth J. F., Zawistowski, Matthew, Zöllner, Sebastian, Lu, Zeyun, Van Den Eeden, Stephen K., Easton, Douglas F., Ambs, Stefan, Edwards, Todd L., Mägi, Reedik, Rebbeck, Timothy R., Fritsche, Lars, Chanock, Stephen J., Berndt, Sonja I., Wiklund, Fredrik, Nakagawa, Hidewaki, Witte, John S., Gaziano, J. Michael, Justice, Amy C., Mancuso, Nick, Terao, Chikashi, Eeles, Rosalind A., Kote-Jarai, Zsofia, Madduri, Ravi K., Conti, David V., and Haiman, Christopher A.

Published
2023
Full Text
View/download PDF

4. Systematic Review on the Cost Effectiveness of Prostate Cancer Screening in Europe

Author

Van Poppel, Hendrik, Collen, Sarah, N’Dow, James, Cornford, Phillip, Gómez Rivas, Juan, Roobol-Bouts, Monique, Beyer, Katharina, Venderbos, Lionne, Helleman, Jozien, Leenen, Renée, Nieboer, Daan, Mulder, Esmée, Lodder, Jeroen, Denijs, Frederique, van den Bergh, Roderick, Talala, Kirsi, Kirkegaard, Pia, Andersen, Berit, Larsen, Mette Bach, Andersen, Sofie Meyer, McKinney, Grace, Hejduk, Karel, Májek, Ondřej, Ngo, Ondřej, Vyskot, Tomáš, Koudelková, Marcela, Zachoval, Roman, Chloupkova, Renata, Hejcmanova, Katerina, van Harten, Meike, Willemse, Peter-Paul, Couespel, Norbert, Moschetti, Riccardo, Morrissey, Mike, Price, Richard, Venegoni, Enea, Konusevska, Agnese, Colceriu, Otilia, Parker, Zoë, Dudek-Godeau, Dorota, Krynicka, Malgorzata, Tupikowski, Krzysztof, Hodyra-Stefaniak, Katarzyna, Litwin, Monika, Pajewska, Monika, Czerw, Aleksandra, Deptała, Andrzej, Amorín, Ángel Gómez, Luque, Silvia Suárez, Parrondo, Carmen Durán, Antelo, Ana Marina Tarrazo, Quinteiro, Montserrat Corujo, Vilaseca, Josep, Borrós, Gemma Cuberas, Bartés, Anna Arnau, Salazar, Juan Pablo, Llauradó, Hector López, Bratt, Ola, Godtman, Rebecka, Järbur, Emil, Jiborn, Thomas, Bjartell, Anders, Holst, Anna, Alterbeck, Max, Patašius, Aušvydas, Miksiene, Gintare, Smailytė, Giedrė, Mickeviciute, Ugne, Annemans, Lieven, Hutsebaut, Pieter-Jan, Vynckier, Pieter, Kidd, Robert, O’Brien, Michael, Keon, Paula, Lynch, Carolyne, Rooney, Michael, Kivi, Martin, Galvin, David, Rogers, Eamonn, Nolan, Eileen, Sweeney, Paul, Horgan, Gillian, Frese, Thomas, Denny, Kathleen, Bennett, Cate, O’Connor, Amy, Coghlan, Sarah, Le Roux, Ricky, Robb, Karen, Basu, Partha, Chandran, Arunah, Carvalho, Andre, Singh, Deependra, Palaniraja, Sathishrajaa, Otero-García, Milagros, Briers, Erik, Lantz, Anna, Eneqvist, Lisa Jelf, Raes, Sarah, Amrouch, Cheïma, Lindgren, Peter, Leenen, Renée C.A., Venderbos, Lionne D.F., van Harten, Meike J., Chloupková, Renata, Vasilyeva, Vera, Rivas, Juan Gomez, van den Bergh, Roderick C.N., Van Poppel, Hein, and Roobol, Monique J.

Published
2024
Full Text
View/download PDF

6. Active Surveillance for Men Younger than 60 Years or with Intermediate-risk Localized Prostate Cancer. Descriptive Analyses of Clinical Practice in the Movember GAP3 Initiative.

Author

Remmers, Sebastiaan, Helleman, Jozien, Nieboer, Daan, Trock, Bruce, Hyndman, Matthew E, Moore, Caroline M, Gnanapragasam, Vincent, Shiong Lee, Lui, Elhage, Oussama, Klotz, Laurence, Carroll, Peter, Pickles, Tom, Bjartell, Anders, Robert, Grégoire, Frydenberg, Mark, Sugimoto, Mikio, Ehdaie, Behfar, Morgan, Todd M, Rubio-Briones, Jose, Semjonow, Axel, Bangma, Chris H, Roobol, Monique J, and Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium

Subjects
Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium, Active surveillance, Disease progression, Prostatic neoplasms, Patient Safety, Aging, Prostate Cancer, Urologic Diseases, Cancer
Abstract

BackgroundActive surveillance (AS) is a management option for men diagnosed with low-risk prostate cancer. Opinions differ on whether it is safe to include young men (≤60 yr) or men with intermediate-risk disease.ObjectiveTo assess whether reasons for discontinuation, treatment choice after AS, and adverse pathology at radical prostatectomy (RP; N1, or ≥GG3, or ≥pT3) differ for men ≤60 yr or those with European Association of Urology (EAU) intermediate-risk disease from those for men >60 yr or those with EAU low-risk disease.Design setting and participantsWe analyzed data from 5411 men ≤60 yr and 14 959 men >60 yr, 14 064 men with low-risk cancer, and 2441 men with intermediate-risk cancer, originating from the GAP3 database (21 169 patients/27 cohorts worldwide).Outcome measurements and statistical analysisCumulative incidence curves were used to estimate the rates of AS discontinuation and treatment choice.Results and limitationsThe probability of discontinuation of AS due to disease progression at 5 yr was similar for men aged ≤60 yr (22%) and those >60 yr (25%), as well as those of any age with low-risk disease (24%) versus those with intermediate-risk disease (24%). Men with intermediate-risk disease are more prone to discontinue AS without evidence of progression than men with low-risk disease (at 1/5 yr: 5.9%/14.2% vs 2.0%/8.8%). Adverse pathology at RP was observed in 32% of men ≤60 yr compared with 36% of men >60 yr (p = 0.029), and in 34% with low-risk disease compared with 40% with intermediate-risk disease (p = 0.048).ConclusionsOur descriptive analysis of AS practices worldwide showed that the risk of progression during AS is similar across the age and risk groups studied. The proportion of adverse pathology was higher among men >60 yr than among men ≤60 yr. These results suggest that men ≤60 yr and those with EAU intermediate-risk disease should not be excluded from opting for AS as initial management.Patient summaryData from 27 international centers reflecting daily clinical practice suggest that younger men or men with intermediate-risk prostate cancer do not hold greater risk for disease progression during active surveillance.

Published
2022

8. Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the G.A.P.3 global consortium database

Author

Beckmann, Kerri R, Bangma, Chris H, Helleman, Jozien, Bjartell, Anders, Carroll, Peter R, Morgan, Todd, Nieboer, Daan, Santaolalla, Aida, Trock, Bruce J, Valdagni, Riccardo, Roobol, Monique J, Trock, Bruce, Ehdaie, Behfar, Carroll, Peter, Filson, Christopher, Logothetis, Christopher, Klotz, Laurence, Pickles, Tom, Hyndman, Eric, Moore, Caroline, Gnanapragasam, Vincent, Van Hemelrijck, Mieke, Dasgupta, Prokar, Bangma, Chris, Roobol, Monique, Villers, Arnauld, Robert, Grégoire, Semjonow, Axel, Rannikko, Antti, Perry, Antoinette, Hugosson, Jonas, Rubio‐Briones, Jose, Hefermehl, Lukas, Shiong, Lee Lui, Frydenberg, Mark, Stricker, Phillip, Sugimoto, Mikio, Chung, Byung Ha, van der Kwast, Theo, van der Linden, Wim, Hulsen, Tim, Ruwe, Boris, van Hooft, Peter, Steyerberg, Ewout, Beckmann, Kerri, Denton, Brian, Hayen, Andrew, Boutros, Paul, Guo, Wei, Benfante, Nicole, Cowan, Janet, Patil, Dattatraya, Park, Lauren, Ferrante, Stephanie, Mamedov, Alexandre, LaPointe, Vincent, Crump, Trafford, Stavrinides, Vasilis, Kimberly‐Duffell, Jenna, Olivier, Jonathan, Rancati, Tiziana, Ahlgren, Helén, Mascarós, Juanma, Löfgren, Annica, Lehmann, Kurt, Lin, Catherine Han, Cusick, Thomas, Hirama, Hiromi, Lee, Kwang Suk, Jenster, Guido, Auvinen, Anssi, Haider, Masoom, van Bochove, Kees, Kouspou, Michelle, and Paich, Kellie

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Urologic Diseases, Aging, Prevention, Cancer, Prostate Cancer, Clinical Research, Biopsy, Disease Progression, Humans, Male, Neoplasm Grading, Prostate, Prostate-Specific Antigen, Prostatic Neoplasms, Watchful Waiting, active surveillance, biopsy schedule, prostate cancer, treatment, upgrading, Global Action Plan Active Surveillance Prostate Cancer [G.A.P.3] Consortium, Paediatrics and Reproductive Medicine, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

BackgroundThe optimal interval for repeat biopsy during active surveillance (AS) for prostate cancer is yet to be defined. This study examined whether risk of upgrading (to grade group ≥ 2) or risk of converting to treatment varied according to intensity of repeat biopsy using data from the GAP3 consortium's global AS database.Materials and methodsIntensity of surveillance biopsy schedules was categorized according to centers' protocols: (a) Prostate Cancer Research International Active Surveillance project (PRIAS) protocols with biopsies at years 1, 4, and 7 (10 centers; 7532 men); (b) biennial biopsies, that is, every other year (8 centers; 4365 men); and (c) annual biopsy schedules (4 centers; 1602 men). Multivariable Cox regression was used to compare outcomes according to biopsy intensity.ResultsOut of the 13,508 eligible participants, 56% were managed according to PRIAS protocols (biopsies at years 1, 4, and 7), 32% via biennial biopsy, and 12% via annual biopsy. After adjusting for baseline characteristics, risk of converting to treatment was greater for those on annual compared with PRIAS biopsy schedules (hazard ratio [HR] = 1.66; 95% confidence interval [CI] = 1.51-1.83; p

Published
2022

9. Unanswered questions in prostate cancer — findings of an international multi-stakeholder consensus by the PIONEER consortium

Author

Omar, Muhammad Imran, MacLennan, Steven, Ribal, Maria J., Roobol, Monique J., Dimitropoulos, Konstantinos, van den Broeck, Thomas, MacLennan, Sara J., Axelsson, Susan Evans, Gandaglia, Giorgio, Willemse, Peter-Paul, Mastris, Ken, Ransohoff, John Butler, Devecseri, Zsuzsanna, Abbott, Thomas, De Meulder, Bertrand, Bjartell, Anders, Asiimwe, Alex, and N’Dow, James

Published
2023
Full Text
View/download PDF

11. Predictive Models for Assessing Patients’ Response to Treatment in Metastatic Prostate Cancer: A Systematic Review

Author

Lawlor, Ailbhe, Lin, Carol, Gómez Rivas, Juan, Ibáñez, Laura, Abad López, Pablo, Willemse, Peter-Paul, Imran Omar, Muhammad, Remmers, Sebastiaan, Cornford, Philip, Rajwa, Pawel, Nicoletti, Rossella, Gandaglia, Giorgio, Yuen-Chun Teoh, Jeremy, Moreno Sierra, Jesús, Golozar, Asieh, Bjartell, Anders, Evans-Axelsson, Susan, N'Dow, James, Zong, Jihong, Ribal, Maria J., Roobol, Monique J., Van Hemelrijck, Mieke, and Beyer, Katharina

Published
2024
Full Text
View/download PDF

12. Clinical Characterization of Patients Diagnosed with Prostate Cancer and Undergoing Conservative Management: A PIONEER Analysis Based on Big Data

Author

Gandaglia, Giorgio, Pellegrino, Francesco, Golozar, Asieh, De Meulder, Bertrand, Abbott, Thomas, Achtman, Ariel, Imran Omar, Muhammad, Alshammari, Thamir, Areia, Carlos, Asiimwe, Alex, Beyer, Katharina, Bjartell, Anders, Campi, Riccardo, Cornford, Philip, Falconer, Thomas, Feng, Qi, Gong, Mengchun, Herrera, Ronald, Hughes, Nigel, Hulsen, Tim, Kinnaird, Adam, Lai, Lana Y.H., Maresca, Gianluca, Mottet, Nicolas, Oja, Marek, Prinsen, Peter, Reich, Christian, Remmers, Sebastiaan, Roobol, Monique J., Sakalis, Vasileios, Seager, Sarah, Smith, Emma J., Snijder, Robert, Steinbeisser, Carl, Thurin, Nicolas H., Hijazy, Ayman, van Bochove, Kees, Van den Bergh, Roderick C.N., Van Hemelrijck, Mieke, Willemse, Peter-Paul, Williams, Andrew E., Zounemat Kermani, Nazanin, Evans-Axelsson, Susan, Briganti, Alberto, and N'Dow, James

Published
2024
Full Text
View/download PDF

13. How Can We Improve Patient-Clinician Communication for Men Diagnosed with Prostate Cancer?

Author

Beyer, Katharina, Lawlor, Ailbhe, Remmers, Sebastiaan, Bezuidenhout, Carla, Gómez Rivas, Juan, Venderbos, Lionne D.F., Smith, Emma J., Gandaglia, Giorgio, MacLennan, Steven, MacLennan, Sara J., Bjartell, Anders, Briganti, Alberto, Cornford, Philip, Evans-Axelsson, Susan, Ribal, Maria J., N'Dow, James, Briers, Erik, Roobol, Monique J., and Van Hemelrijck, Mieke

Published
2024
Full Text
View/download PDF

14. Genetic factors associated with prostate cancer conversion from active surveillance to treatment

Author

Jiang, Yu, Meyers, Travis J, Emeka, Adaeze A, Cooley, Lauren Folgosa, Cooper, Phillip R, Lancki, Nicola, Helenowski, Irene, Kachuri, Linda, Lin, Daniel W, Stanford, Janet L, Newcomb, Lisa F, Kolb, Suzanne, Finelli, Antonio, Fleshner, Neil E, Komisarenko, Maria, Eastham, James A, Ehdaie, Behfar, Benfante, Nicole, Logothetis, Christopher J, Gregg, Justin R, Perez, Cherie A, Garza, Sergio, Kim, Jeri, Marks, Leonard S, Delfin, Merdie, Barsa, Danielle, Vesprini, Danny, Klotz, Laurence H, Loblaw, Andrew, Mamedov, Alexandre, Goldenberg, S Larry, Higano, Celestia S, Spillane, Maria, Wu, Eugenia, Carter, H Ballentine, Pavlovich, Christian P, Mamawala, Mufaddal, Landis, Tricia, Carroll, Peter R, Chan, June M, Cooperberg, Matthew R, Cowan, Janet E, Morgan, Todd M, Siddiqui, Javed, Martin, Rabia, Klein, Eric A, Brittain, Karen, Gotwald, Paige, Barocas, Daniel A, Dallmer, Jeremiah R, Gordetsky, Jennifer B, Steele, Pam, Kundu, Shilajit D, Stockdale, Jazmine, Roobol, Monique J, Venderbos, Lionne DF, Sanda, Martin G, Arnold, Rebecca, Patil, Dattatraya, Evans, Christopher P, Dall’Era, Marc A, Vij, Anjali, Costello, Anthony J, Chow, Ken, Corcoran, Niall M, Rais-Bahrami, Soroush, Phares, Courtney, Scherr, Douglas S, Flynn, Thomas, Karnes, R Jeffrey, Koch, Michael, Dhondt, Courtney Rose, Nelson, Joel B, McBride, Dawn, Cookson, Michael S, Stratton, Kelly L, Farriester, Stephen, Hemken, Erin, Stadler, Walter M, Pera, Tuula, Banionyte, Deimante, Bianco, Fernando J, Lopez, Isabel H, Loeb, Stacy, Taneja, Samir S, Byrne, Nataliya, Amling, Christopher L, Martinez, Ann, Boileau, Luc, Gaylis, Franklin D, Petkewicz, Jacqueline, Kirwen, Nicholas, Helfand, Brian T, Xu, Jianfeng, Scholtens, Denise M, Catalona, William J, and Witte, John S

Subjects
Biological Sciences, Genetics, Clinical Research, Prevention, Human Genome, Clinical Trials and Supportive Activities, Urologic Diseases, Aging, Cancer, Prostate Cancer, genetics, genome-wide association study, prostate, prostatic neoplasms
Abstract

Men diagnosed with low-risk prostate cancer (PC) are increasingly electing active surveillance (AS) as their initial management strategy. While this may reduce the side effects of treatment for prostate cancer, many men on AS eventually convert to active treatment. PC is one of the most heritable cancers, and genetic factors that predispose to aggressive tumors may help distinguish men who are more likely to discontinue AS. To investigate this, we undertook a multi-institutional genome-wide association study (GWAS) of 5,222 PC patients and 1,139 other patients from replication cohorts, all of whom initially elected AS and were followed over time for the potential outcome of conversion from AS to active treatment. In the GWAS we detected 18 variants associated with conversion, 15 of which were not previously associated with PC risk. With a transcriptome-wide association study (TWAS), we found two genes associated with conversion (MAST3, p = 6.9×10-7 and GAB2, p = 2.0×10-6). Moreover, increasing values of a previously validated 269-variant genetic risk score (GRS) for PC was positively associated with conversion (e.g., comparing the highest to the two middle deciles gave a hazard ratio [HR] = 1.13; 95% Confidence Interval [CI]= 0.94-1.36); whereas, decreasing values of a 36-variant GRS for prostate-specific antigen (PSA) levels were positively associated with conversion (e.g., comparing the lowest to the two middle deciles gave a HR = 1.25; 95% CI, 1.04-1.50). These results suggest that germline genetics may help inform and individualize the decision of AS-or the intensity of monitoring on AS-versus treatment for the initial management of patients with low-risk PC.

Published
2022

15. Association between circulating inflammatory markers and adult cancer risk: a Mendelian randomization analysis

Author

Landi, Maria Teresa, Stevens, Victoria, Wang, Ying, Albanes, Demetrios, Caporaso, Neil, Brennan, Paul, Amos, Christopher I., Shete, Sanjay, Hung, Rayjean J., Bickeböller, Heike, Risch, Angela, Houlston, Richard, Lam, Stephen, Tardon, Adonina, Chen, Chu, Bojesen, Stig E., Johansson, Mattias, Wichmann, H-Erich, Christiani, David, Rennert, Gadi, Arnold, Susanne, Field, John K., Le Marchand, Loic, Melander, Olle, Brunnström, Hans, Liu, Geoffrey, Andrew, Angeline, Kiemeney, Lambertus A., Shen, Hongbing, Zienolddiny, Shan, Grankvist, Kjell, Johansson, Mikael, Teare, M. Dawn, Hong, Yun-Chul, Yuan, Jian-Min, Lazarus, Philip, Schabath, Matthew B., Aldrich, Melinda C., Eeles, Rosalind A., Haiman, Christopher A., Kote-Jarai, Zsofia, Schumacher, Fredrick R., Benlloch, Sara, Al Olama, Ali Amin, Muir, Kenneth R., Berndt, Sonja I., Conti, David V., Wiklund, Fredrik, Chanock, Stephen, Tangen, Catherine M., Batra, Jyotsna, Clements, Judith A., Grönberg, Henrik, Pashayan, Nora, Schleutker, Johanna, Albanes, Demetrius, Weinstein, Stephanie J., Wolk, Alicja, West, Catharine M.L., Mucci, Lorelei A., Cancel-Tassin, Géraldine, Koutros, Stella, Sørensen, Karina Dalsgaard, Grindedal, Eli Marie, Neal, David E., Hamdy, Freddie C., Donovan, Jenny L., Travis, Ruth C., Hamilton, Robert J., Ingles, Sue Ann, Rosenstein, Barry S., Lu, Yong-Jie, Giles, Graham G., MacInnis, Robert J., Kibel, Adam S., Vega, Ana, Kogevinas, Manolis, Penney, Kathryn L., Park, Jong Y., Stanfrod, Janet L., Cybulski, Cezary, Nordestgaard, Børge G., Nielsen, Sune F., Brenner, Hermann, Maier, Christiane, Logothetis, Christopher J., John, Esther M., Teixeira, Manuel R., Neuhausen, Susan L., De Ruyck, Kim, Razack, Azad, Newcomb, Lisa F., Lessel, Davor, Kaneva, Radka, Usmani, Nawaid, Claessens, Frank, Townsend, Paul A., Castelao, Jose Esteban, Roobol, Monique J., Menegaux, Florence, Khaw, Kay-Tee, Cannon-Albright, Lisa, Pandha, Hardev, Thibodeau, Stephen N., Hunter, David J., Kraft, Peter, Blot, William J., Riboli, Elio, Yarmolinsky, James, Robinson, Jamie W., Mariosa, Daniela, Karhunen, Ville, Huang, Jian, Dimou, Niki, Murphy, Neil, Burrows, Kimberley, Bouras, Emmanouil, Smith-Byrne, Karl, Lewis, Sarah J., Galesloot, Tessel E., Vermeulen, Sita, Martin, Paul, Hou, Lifang, Newcomb, Polly A., White, Emily, Wu, Anna H., Le Marchand, Loïc, Phipps, Amanda I., Buchanan, Daniel D., Zhao, Sizheng Steven, Gill, Dipender, Chanock, Stephen J., Purdue, Mark P., Davey Smith, George, Herzig, Karl-Heinz, Järvelin, Marjo-Riitta, Amos, Chris I., Dehghan, Abbas, Gunter, Marc J., Tsilidis, Kostas K., and Martin, Richard M.

Published
2024
Full Text
View/download PDF

17. Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer.

Author

Karunamuni, Roshan A, Huynh-Le, Minh-Phuong, Fan, Chun C, Thompson, Wesley, Eeles, Rosalind A, Kote-Jarai, Zsofia, Muir, Kenneth, Lophatananon, Artitaya, UKGPCS collaborators, Schleutker, Johanna, Pashayan, Nora, Batra, Jyotsna, APCB BioResource (Australian Prostate Cancer BioResource), Grönberg, Henrik, Walsh, Eleanor I, Turner, Emma L, Lane, Athene, Martin, Richard M, Neal, David E, Donovan, Jenny L, Hamdy, Freddie C, Nordestgaard, Børge G, Tangen, Catherine M, MacInnis, Robert J, Wolk, Alicja, Albanes, Demetrius, Haiman, Christopher A, Travis, Ruth C, Stanford, Janet L, Mucci, Lorelei A, West, Catharine ML, Nielsen, Sune F, Kibel, Adam S, Wiklund, Fredrik, Cussenot, Olivier, Berndt, Sonja I, Koutros, Stella, Sørensen, Karina Dalsgaard, Cybulski, Cezary, Grindedal, Eli Marie, Park, Jong Y, Ingles, Sue A, Maier, Christiane, Hamilton, Robert J, Rosenstein, Barry S, Vega, Ana, IMPACT Study Steering Committee and Collaborators, Kogevinas, Manolis, Penney, Kathryn L, Teixeira, Manuel R, Brenner, Hermann, John, Esther M, Kaneva, Radka, Logothetis, Christopher J, Neuhausen, Susan L, Razack, Azad, Newcomb, Lisa F, Canary PASS Investigators, Gamulin, Marija, Usmani, Nawaid, Claessens, Frank, Gago-Dominguez, Manuela, Townsend, Paul A, Roobol, Monique J, Zheng, Wei, Profile Study Steering Committee, Mills, Ian G, Andreassen, Ole A, Dale, Anders M, Seibert, Tyler M, and PRACTICAL Consortium

Subjects
UKGPCS collaborators, APCB BioResource, IMPACT Study Steering Committee and Collaborators, Canary PASS Investigators, Profile Study Steering Committee, PRACTICAL Consortium, Prevention, Urologic Diseases, Cancer, Prostate Cancer, Aging, Urology & Nephrology, Oncology and Carcinogenesis
Abstract

BackgroundPolygenic hazard scores (PHS) can identify individuals with increased risk of prostate cancer. We estimated the benefit of additional SNPs on performance of a previously validated PHS (PHS46).Materials and method180 SNPs, shown to be previously associated with prostate cancer, were used to develop a PHS model in men with European ancestry. A machine-learning approach, LASSO-regularized Cox regression, was used to select SNPs and to estimate their coefficients in the training set (75,596 men). Performance of the resulting model was evaluated in the testing/validation set (6,411 men) with two metrics: (1) hazard ratios (HRs) and (2) positive predictive value (PPV) of prostate-specific antigen (PSA) testing. HRs were estimated between individuals with PHS in the top 5% to those in the middle 40% (HR95/50), top 20% to bottom 20% (HR80/20), and bottom 20% to middle 40% (HR20/50). PPV was calculated for the top 20% (PPV80) and top 5% (PPV95) of PHS as the fraction of individuals with elevated PSA that were diagnosed with clinically significant prostate cancer on biopsy.Results166 SNPs had non-zero coefficients in the Cox model (PHS166). All HR metrics showed significant improvements for PHS166 compared to PHS46: HR95/50 increased from 3.72 to 5.09, HR80/20 increased from 6.12 to 9.45, and HR20/50 decreased from 0.41 to 0.34. By contrast, no significant differences were observed in PPV of PSA testing for clinically significant prostate cancer.ConclusionsIncorporating 120 additional SNPs (PHS166 vs PHS46) significantly improved HRs for prostate cancer, while PPV of PSA testing remained the same.

Published
2021

19. Relationship Between Baseline Prostate-specific Antigen on Cancer Detection and Prostate Cancer Death: Long-term Follow-up from the European Randomized Study of Screening for Prostate Cancer

Author

Remmers, Sebastiaan, Bangma, Chris H., Godtman, Rebecka A., Carlsson, Sigrid V., Auvinen, Anssi, Tammela, Teuvo L.J., Denis, Louis J., Nelen, Vera, Villers, Arnauld, Rebillard, Xavier, Kwiatkowski, Maciej, Recker, Franz, Wyler, Stephen, Zappa, Marco, Puliti, Donella, Gorini, Giuseppe, Paez, Alvaro, Lujan, Marcos, Nieboer, Daan, Schröder, Fritz H., and Roobol, Monique J.

Published
2023
Full Text
View/download PDF

22. Polygenic hazard score is associated with prostate cancer in multi-ethnic populations.

Author

Huynh-Le, Minh-Phuong, Fan, Chun Chieh, Karunamuni, Roshan, Thompson, Wesley K, Martinez, Maria Elena, Eeles, Rosalind A, Kote-Jarai, Zsofia, Muir, Kenneth, Schleutker, Johanna, Pashayan, Nora, Batra, Jyotsna, Grönberg, Henrik, Neal, David E, Donovan, Jenny L, Hamdy, Freddie C, Martin, Richard M, Nielsen, Sune F, Nordestgaard, Børge G, Wiklund, Fredrik, Tangen, Catherine M, Giles, Graham G, Wolk, Alicja, Albanes, Demetrius, Travis, Ruth C, Blot, William J, Zheng, Wei, Sanderson, Maureen, Stanford, Janet L, Mucci, Lorelei A, West, Catharine ML, Kibel, Adam S, Cussenot, Olivier, Berndt, Sonja I, Koutros, Stella, Sørensen, Karina Dalsgaard, Cybulski, Cezary, Grindedal, Eli Marie, Menegaux, Florence, Khaw, Kay-Tee, Park, Jong Y, Ingles, Sue A, Maier, Christiane, Hamilton, Robert J, Thibodeau, Stephen N, Rosenstein, Barry S, Lu, Yong-Jie, Watya, Stephen, Vega, Ana, Kogevinas, Manolis, Penney, Kathryn L, Huff, Chad, Teixeira, Manuel R, Multigner, Luc, Leach, Robin J, Cannon-Albright, Lisa, Brenner, Hermann, John, Esther M, Kaneva, Radka, Logothetis, Christopher J, Neuhausen, Susan L, De Ruyck, Kim, Pandha, Hardev, Razack, Azad, Newcomb, Lisa F, Fowke, Jay H, Gamulin, Marija, Usmani, Nawaid, Claessens, Frank, Gago-Dominguez, Manuela, Townsend, Paul A, Bush, William S, Roobol, Monique J, Parent, Marie-Élise, Hu, Jennifer J, Mills, Ian G, Andreassen, Ole A, Dale, Anders M, Seibert, Tyler M, UKGPCS collaborators, APCB (Australian Prostate Cancer BioResource), NC-LA PCaP Investigators, IMPACT Study Steering Committee and Collaborators, Canary PASS Investigators, Profile Study Steering Committee, and PRACTICAL Consortium

Subjects
UKGPCS collaborators, APCB, NC-LA PCaP Investigators, IMPACT Study Steering Committee and Collaborators, Canary PASS Investigators, Profile Study Steering Committee, PRACTICAL Consortium, Humans, Prostatic Neoplasms, Neoplasm Invasiveness, Multivariate Analysis, Multifactorial Inheritance, Aged, Middle Aged, Ethnic Groups, Male, Self Report, Aging, Urologic Diseases, Cancer, Prostate Cancer
Abstract

Genetic models for cancer have been evaluated using almost exclusively European data, which could exacerbate health disparities. A polygenic hazard score (PHS1) is associated with age at prostate cancer diagnosis and improves screening accuracy in Europeans. Here, we evaluate performance of PHS2 (PHS1, adapted for OncoArray) in a multi-ethnic dataset of 80,491 men (49,916 cases, 30,575 controls). PHS2 is associated with age at diagnosis of any and aggressive (Gleason score ≥ 7, stage T3-T4, PSA ≥ 10 ng/mL, or nodal/distant metastasis) cancer and prostate-cancer-specific death. Associations with cancer are significant within European (n = 71,856), Asian (n = 2,382), and African (n = 6,253) genetic ancestries (p

Published
2021

23. Personalised biopsy schedules based on risk of Gleason upgrading for patients with low-risk prostate cancer on active surveillance.

Author

Tomer, Anirudh, Nieboer, Daan, Roobol, Monique J, Bjartell, Anders, Steyerberg, Ewout W, Rizopoulos, Dimitris, and Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium

Subjects
Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium, Prostate, Humans, Prostatic Neoplasms, Prostate-Specific Antigen, Biopsy, Area Under Curve, Models, Statistical, Risk Assessment, Risk Factors, ROC Curve, Internet, Software, Aged, Middle Aged, Appointments and Schedules, Male, Watchful Waiting, Neoplasm Grading, Clinical Decision-Making, Decision Making, Shared, active surveillance, biopsies, personalised medicine, prostate cancer, shared decision-making, Cancer, Prostate Cancer, Aging, Urologic Diseases, Clinical Research, Prevention, 4.2 Evaluation of markers and technologies, Detection, screening and diagnosis, Good Health and Well Being, Clinical Sciences, Urology & Nephrology
Abstract

ObjectiveTo develop a model and methodology for predicting the risk of Gleason upgrading in patients with prostate cancer on active surveillance (AS) and using the predicted risks to create risk-based personalised biopsy schedules as an alternative to one-size-fits-all schedules (e.g. annually). Furthermore, to assist patients and doctors in making shared decisions on biopsy schedules, by providing them quantitative estimates of the burden and benefit of opting for personalised vs any other schedule in AS. Lastly, to externally validate our model and implement it along with personalised schedules in a ready to use web-application.Patients and methodsRepeat prostate-specific antigen (PSA) measurements, timing and results of previous biopsies, and age at baseline from the world's largest AS study, Prostate Cancer Research International Active Surveillance (PRIAS; 7813 patients, 1134 experienced upgrading). We fitted a Bayesian joint model for time-to-event and longitudinal data to this dataset. We then validated our model externally in the largest six AS cohorts of the Movember Foundation's third Global Action Plan (GAP3) database (>20 000 patients, 27 centres worldwide). Using the model predicted upgrading risks; we scheduled biopsies whenever a patient's upgrading risk was above a certain threshold. To assist patients/doctors in the choice of this threshold, and to compare the resulting personalised schedule with currently practiced schedules, along with the timing and the total number of biopsies (burden) planned, for each schedule we provided them with the time delay expected in detecting upgrading (shorter is better).ResultsThe cause-specific cumulative upgrading risk at the 5-year follow-up was 35% in PRIAS, and at most 50% in the GAP3 cohorts. In the PRIAS-based model, PSA velocity was a stronger predictor of upgrading (hazard ratio [HR] 2.47, 95% confidence interval [CI] 1.93-2.99) than the PSA level (HR 0.99, 95% CI 0.89-1.11). Our model had a moderate area under the receiver operating characteristic curve (0.6-0.7) in the validation cohorts. The prediction error was moderate (0.1-0.2) in theGAP3 cohorts where the impact of the PSA level and velocity on upgrading risk was similar to PRIAS, but large (0.2-0.3) otherwise. Our model required re-calibration of baseline upgrading risk in the validation cohorts. We implemented the validated models and the methodology for personalised schedules in a web-application (http://tiny.cc/biopsy).ConclusionsWe successfully developed and validated a model for predicting upgrading risk, and providing risk-based personalised biopsy decisions in AS of prostate cancer. Personalised prostate biopsies are a novel alternative to fixed one-size-fits-all schedules, which may help to reduce unnecessary prostate biopsies, while maintaining cancer control. The model and schedules made available via a web-application enable shared decision-making on biopsy schedules by comparing fixed and personalised schedules on total biopsies and expected time delay in detecting upgrading.

Published
2021

25. Comparison of biopsy under‐sampling and annual progression using hidden markov models to learn from prostate cancer active surveillance studies

Author

Li, Weiyu, Denton, Brian T, Nieboer, Daan, Carroll, Peter R, Roobol, Monique J, Morgan, Todd M, and consortium, Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Prevention, Aging, Prostate Cancer, Clinical Research, Urologic Diseases, Cancer, Aged, Biopsy, Cohort Studies, Databases, Factual, Disease Progression, Early Detection of Cancer, Humans, Male, Markov Chains, Middle Aged, Models, Statistical, Neoplasm Grading, Prostate-Specific Antigen, Prostatic Neoplasms, Risk Assessment, Watchful Waiting, active surveillance, biopsy, biopsy under&#8208, sampling, cancer progression, hidden Markov model, prostate cancer, Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium, biopsy under-sampling, Biochemistry and Cell Biology, Oncology and carcinogenesis
Abstract

This study aimed to estimate the rates of biopsy undersampling and progression for four prostate cancer (PCa) active surveillance (AS) cohorts within the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium. We used a hidden Markov model (HMM) to estimate factors that define PCa dynamics for men on AS including biopsy under-sampling and progression that are implied by longitudinal data in four large cohorts included in the GAP3 database. The HMM was subsequently used as the basis for a simulation model to evaluate the biopsy strategies previously proposed for each of these cohorts. For the four AS cohorts, the estimated annual progression rate was between 6%-13%. The estimated probability of a biopsy successfully sampling undiagnosed non-favorable risk cancer (biopsy sensitivity) was between 71% and 80%. In the simulation study of patients diagnosed with favorable risk cancer at age 50, the mean number of biopsies performed before age 75 was between 4.11 and 12.60, depending on the biopsy strategy. The mean delay time to detection of non-favorable risk cancer was between 0.38 and 2.17 years. Biopsy undersampling and progression varied considerably across study cohorts. There was no single best biopsy protocol that is optimal for all cohorts, because of the variation in biopsy under-sampling error and annual progression rates across cohorts. All strategies demonstrated diminishing benefits from additional biopsies.

Published
2020

26. Personalized Decision Making for Biopsies in Prostate Cancer Active Surveillance Programs

Author

Tomer, Anirudh, Rizopoulos, Dimitris, Nieboer, Daan, Drost, Frank-Jan, Roobol, Monique J., and Steyerberg, Ewout W.

Subjects
Statistics - Applications, Statistics - Methodology
Abstract

Background: Low-risk prostate cancer patients enrolled in active surveillance programs commonly undergo biopsies for examination of cancer progression. Biopsies are conducted as per a fixed and frequent schedule (e.g., annual biopsies). Since biopsies are burdensome, patients do not always comply with the schedule, which increases the risk of delayed detection of cancer progression. Objective: Our aim is to better balance the number of biopsies (burden) and the delay in detection of cancer progression (less is beneficial), by personalizing the decision of conducting biopsies. Data Sources: We use patient data of the world's largest active surveillance program (PRIAS). It enrolled 5270 patients, had 866 cancer progressions, and an average of nine prostate-specific antigen (PSA) and five digital rectal examination (DRE) measurements per patient. Methods: Using joint models for time-to-event and longitudinal data, we model the historical DRE and PSA measurements, and biopsy results of a patient at each follow-up visit. This results in a visit and patient-specific cumulative risk of cancer progression. If this risk is above a certain threshold, we schedule a biopsy. We compare this personalized approach with the currently practiced biopsy schedules via an extensive and realistic simulation study, based on a replica of the patients from the PRIAS program. Results: The personalized approach saved a median of six biopsies (median: 4, IQR: 2-5), compared to the annual schedule (median: 10, IQR: 3-10). However, the delay in detection of progression (years) is similar for the personalized (median: 0.7, IQR: 0.3-1.0) and the annual schedule (median: 0.5, IQR: 0.3-0.8). Conclusions: We conclude that personalized schedules provide substantially better balance in the number of biopsies per detected progression for men with low-risk prostate cancer.

Published
2019

28. Best Current Practice and Research Priorities in Active Surveillance for Prostate Cancer—A Report of a Movember International Consensus Meeting

Author

Moore, Caroline M., King, Lauren E., Withington, John, Amin, Mahul B., Andrews, Mark, Briers, Erik, Chen, Ronald C., Chinegwundoh, Francis I., Cooperberg, Matthew R., Crowe, Jane, Finelli, Antonio, Fitch, Margaret I., Frydenberg, Mark, Giganti, Francesco, Haider, Masoom A., Freeman, John, Gallo, Joseph, Gibbs, Stephen, Henry, Anthony, James, Nicholas, Kinsella, Netty, Lam, Thomas B.L., Lichty, Mark, Loeb, Stacy, Mahal, Brandon A., Mastris, Ken, Mitra, Anita V., Merriel, Samuel W.D., van der Kwast, Theodorus, Van Hemelrijck, Mieke, Palmer, Nynikka R., Paterson, Catherine C., Roobol, Monique J., Segal, Phillip, Schraidt, James A., Short, Camille E., Siddiqui, M. Minhaj, Tempany, Clare M.C., Villers, Arnaud, Wolinsky, Howard, and MacLennan, Steven

Published
2023
Full Text
View/download PDF

30. Mapping European Association of Urology Guideline Practice Across Europe: An Audit of Androgen Deprivation Therapy Use Before Prostate Cancer Surgery in 6598 Cases in 187 Hospitals Across 31 European Countries

Author

Heidegger, Isabel, Resch, Johannes Mischinger Irene, Turba, Simon, Zeder, Robin, Lodeta, Braninimir, Van Praet, Charles, Ghysel, Christophe, Arentsen, Harm C., Beysens, Matthias, Vinckier, Marie-Hélène, Mottrie, Alexandre, de Groote, Ruben, Timev, Aleksandar Ivanov, Georgiev, Marincho Ivanov, Yanev, Krassimir Prodanov, Mladenov, Boris, Ivanov, Atanas Slavchev, Antonov, Petar, Valkanov, Stanislav, Tomašković, Igor, Kulis, Tomislav, Bokarica, Pero, Pavlović, Oliver, Krajina, Vinko, Situm, Marijan, Boban, Toni, Soric, Tomislav, Vidic, Ivan, Benko, Goran, Peršec, Zoran, Sović, Tomislav, Zachoval, Roman, Stejskal, Jiri, Capoun, Otakar, Pitra, Tomáš, Gojdič, Marek, Babjuk, Marek, Novák, Vojtěch, Grepl, Michal, Broul, Marek, Novák, Jan, Lund, Lars, Nordström Joensen, Ulla, Borre, Michael, Veskimäe, Priit, Baum, Peep, Tamm, Toomas, Okas, Rauno, Jämsä, Pyry, Lahdensuo, Kanerva, Siltari, Sirkku, Seikkula, Heikki, Palmberg, Christian, Isotalo, Taina, Fiard, Gaelle, Verrier, Cecile, Wiedemann, Laura, Lecornet, Emilie, Leon, Priscilla, Millet, Clementine, Ponzio, Charles, Ploussard, Guillaume, Xylinas, Evanguelos, Ingels, Alexandre, Bigot, Pierre, Le Corre, Vincent, Audenet, François, Berg, Sebastian, Palisaar, Rein-Jueri, Heidenreich, Axel, Seelemeyer, Felix, Krege, Susanne, Leyh-Bannurah, Sami-Ramzi, Witt, Jörn H., Abdirahman, Ayanle, Truß, Michael C., Kranz, Jennifer, Andreas, Karagiannis, Vassileios, Tzortzis, Andreas, Andreou, Paparidis, Spyridon, Davis, Nikolaos Ferakis Niall F., Keane, Kevin G., Fuentes, Adrian, Scuderi, Simone, Barletta, Francesco, Manfredi, Matteo, Porpiglia, Francesco, Cerruto, Maria Angela, Antonelli, Alessandro, Esperto, Francesco, Rossanese, Marta, Veneziano, Domenico, Castelli, Tommaso, Mantica, Roberto La Rocca Marcello Scarcia Guglielmo, Rebuffo, Silvia, Pomara, Giorgio, Pavan, Nicola, Silvestri, Tommaso, Reale, Giulio Francesco, Polara, Andrea, Falagario, Ugo Giovanni, Carrieri, Giuseppe, Ferrari, Giovanni, Brausi, Maurizio, Orecchia, Luca, Annino, Filippo, Kazlauskas, Gražvydas, Stavridis, Sotir, Radovic, Nenad, Vukovic, Marko, van der Slot, Margaretha Adriana, Bruins, Harman Maxim, van Oort, Inge, Witjes, Fred, van der Poel, Henk, Beisland, Christian, Lilleåsenm, Gunder, Müller, Stig, Haug, Erik S., Dimmen, Magne, Czech, Anna K., Nyk, Lukasz, Jaskulski, Jaroslaw, Ratajczyk, Krzysztof, Azevedo, Nuno, Braga, Isaac, Pereira, João, Lúcio, Rui, Pina, João, da Silva, Edgar Miguel Calvo Loureiro Tavares, Furriel, Frederico, Mota, Paulo, Rodrigues, Miguel, Radavoi, George Daniel, Crisan, Nicolae, Andras, Iulia, Robert, Stoica, Bratu, Ovidiu, Surcel, Cristian, Kotov, Sergei, Malkhasyan, Vigen, Petrov, Sergei, Reva, Sergei, Bumbasirevic, Uros, Kováčik, Viktor, Perečinský, Ivan, Rybár, Ľuboš, Šulgan, Ján, Briš, Lukáš, Jursová, Katarína, Chovan, Miroslav, Kička, Tomáš, Taskovska, Milena, Kovačič, Rok, Miklavžina, Andraž, Alvarez-Maestro, Mario, De Castro, Javier Mayor, Aragón-Chamizo, Juan, Sutil, Raquel Sopeña, Perrello, Carmen Garau, Vilaseca, Antoni, Perez, Jorge Huguet, Ovide, Julia Aumatell, Planas, Jacques, Borque-Fernando, Angel, Sánchez-Izquierdo, Elena, Jimenez, Jose Luis Marenco, Lendínez-Cano, Guillermo, Puche-Sanz, Ignacio, Garcia-Baquero, Rodrigo, Esteban, Mario Domínguez, Pérez-Fentes, Daniel, Serván, Patricia Parra, Koskela, Lotta Renström, Stranne, Johan, Scholtz, Bianca, Torbrand, Christian, Wagenius, Magnus, Ugge, Henrik, Örtegren, Joakim, Langenauer, Janine, Zumstein, Valentin, Schmid, Hans Peter, Rieken, Malte, Saba, Karim, Strebel, Raeto T., Mortezavi, Ashkan, Rentsch, Cyrill, Roth, Beat, Eberli, Daniel, Pascal, Oechslin, Auer, Rebecca, John, Hubert, Thalmann, George N., Baltacı, Sümer, Mungan, Aydın, Sözen, Sinan, Cetin, Serhat, Aslan, Guven, Türkeri, Levent, İzol, Volkan, Demirdağ, Çetin, Ozden, Sami Berk, Toktaş, Gökhan, Sarikaya, Şaban, Tinay, İlker, Müezzinoğlu, Talha, Erbatu, Oguzcan, Sagnak, Levent, Akdoğan, Bülent, Can, Cavit, Şahin, Hayrettin, Yazıcı, Cenk Murat, Volkov, Serhii, Shulyak, Olexandr, Douglas, David, Hemmant, Joshua, El-Taji, Omar, Ahmad, Imran, Nalagatla, Sarika, Janebdar, Husay, Veeratterapillay, Rajan, Rai, Bhavan, Conroy, Samantha, Cumberbatch, Marcus, Malde, Sachin, MacLennan, Steven, Duncan, Eilidh, Dunsmore, Jennifer, Fullwood, Louise, Lumen, Nicolaas, Plass, Karin, Ribal, Maria J., Roobol, Monique J., Nieboer, Daan, Schouten, Natasha, Skolarus, Ted A., Smith, Emma Jane, N'Dow, James, Mottet, Nicolas, and Briganti, Alberto

Published
2023
Full Text
View/download PDF

32. Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium

Author

Van Hemelrijck, Mieke, Ji, Xi, Helleman, Jozien, Roobol, Monique J, van der Linden, Wim, Nieboer, Daan, Bangma, Chris H, Frydenberg, Mark, Rannikko, Antti, Lee, Lui S, Gnanapragasam, Vincent J, Kattan, Mike W, Trock, Bruce, Ehdaie, Behfar, Carroll, Peter, Filson, Christopher, Kim, Jeri, Logothetis, Christopher, Morgan, Todd, Klotz, Laurence, Pickles, Tom, Hyndman, Eric, Moore, Caroline M, Gnanapragasam, Vincent, Dasgupta, Prokar, Bangma, Chris, Roobol, Monique, Villers, Arnauld, Valdagni, Riccardo, Perry, Antoinette, Hugosson, Jonas, Rubio-Briones, Jose, Bjartell, Anders, Hefermehl, Lukas, Shiong, Lee Lui, Kakehi, Yoshiyuki, Chung, Byung Ha, van der Kwast, Theo, Obbink, Henk, Hulsen, Tim, de Jonge, Cees, Kattan, Mike, Xinge, Ji, Muir, Kenneth, Lophatananon, Artitaya, Fahey, Michael, Steyerberg, Ewout, Zhang, Liying, Santa Olalla, Aida, Beckmann, Kerri, Denton, Brian, Hayen, Andrew, Boutros, Paul, Guo, Wei, Benfante, Nicole, Cowan, Janet, Patil, Dattatraya, Tolosa, Emily, Kim, Tae-Kyung, Mamedov, Alexandre, La Pointe, Vincent, Crump, Trafford, Kimberly-Duffell, Jenna, Santaolalla, Aida, Olivier, Jonathan, Rancati, Tiziana, Ahlgren, Helén, Mascarós, Juanma, Löfgren, Annica, Lehmann, Kurt, Lin, Catherine Han, Hirama, Hiromi, Lee, Kwang Suk, Jenster, Guido, Auvinen, Anssi, Haider, Masoom, van Bochove, Kees, Carter, Ballentine, Gledhill, Sam, Buzza, Mark, and Bruinsma, Sophie

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Prostate Cancer, Aging, Prevention, Urologic Diseases, Cancer, Good Health and Well Being, Aged, Asia, Australia, Biopsy, Cause of Death, Clinical Decision-Making, Databases, Factual, Disease Progression, Early Detection of Cancer, Europe, Humans, Kallikreins, Male, Middle Aged, North America, Patient Dropouts, Predictive Value of Tests, Prostate-Specific Antigen, Prostatic Neoplasms, Risk Assessment, Risk Factors, Time Factors, Watchful Waiting, Prostate cancer, Active surveillance, Discontinuation, Worldwide, Members of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance GAP3 consortium, Urology & Nephrology, Clinical sciences
Abstract

BackgroundCareful assessment of the reasons for discontinuation of active surveillance (AS) is required for men with prostate cancer (PCa).ObjectiveUsing Movember's Global Action Plan Prostate Cancer Active Surveillance initiative (GAP3) database, we report on reasons for AS discontinuation.Design, setting, and participantsWe compared data from 10296 men on AS from 21 centres across 12 countries.Outcome measurements and statistical analysisCumulative incidence methods were used to estimate the cumulative incidence rates of AS discontinuation.Results and limitationsDuring 5-yr follow-up, 27.5% (95% confidence interval [CI]: 26.4-28.6%) men showed signs of disease progression, 12.8% (95% CI: 12.0-13.6%) converted to active treatment without evidence of progression, 1.7% (95% CI: 1.5-2.0%) continued to watchful waiting, and 1.7% (95% CI: 1.4-2.1%) died from other causes. Of the 7049 men who remained on AS, 2339 had follow-up for >5yr, 4561 had follow-up for

Published
2019

33. Author Correction: Germline variation at 8q24 and prostate cancer risk in men of European ancestry.

Author

Matejcic, Marco, Saunders, Edward J, Dadaev, Tokhir, Brook, Mark N, Wang, Kan, Sheng, Xin, Olama, Ali Amin Al, Schumacher, Fredrick R, Ingles, Sue A, Govindasami, Koveela, Benlloch, Sara, Berndt, Sonja I, Albanes, Demetrius, Koutros, Stella, Muir, Kenneth, Stevens, Victoria L, Gapstur, Susan M, Tangen, Catherine M, Batra, Jyotsna, Clements, Judith, Gronberg, Henrik, Pashayan, Nora, Schleutker, Johanna, Wolk, Alicja, West, Catharine, Mucci, Lorelei, Kraft, Peter, Cancel-Tassin, Géraldine, Sorensen, Karina D, Maehle, Lovise, Grindedal, Eli M, Strom, Sara S, Neal, David E, Hamdy, Freddie C, Donovan, Jenny L, Travis, Ruth C, Hamilton, Robert J, Rosenstein, Barry, Lu, Yong-Jie, Giles, Graham G, Kibel, Adam S, Vega, Ana, Bensen, Jeanette T, Kogevinas, Manolis, Penney, Kathryn L, Park, Jong Y, Stanford, Janet L, Cybulski, Cezary, Nordestgaard, Børge G, Brenner, Hermann, Maier, Christiane, Kim, Jeri, Teixeira, Manuel R, Neuhausen, Susan L, De Ruyck, Kim, Razack, Azad, Newcomb, Lisa F, Lessel, Davor, Kaneva, Radka, Usmani, Nawaid, Claessens, Frank, Townsend, Paul A, Gago-Dominguez, Manuela, Roobol, Monique J, Menegaux, Florence, Khaw, Kay-Tee, Cannon-Albright, Lisa A, Pandha, Hardev, Thibodeau, Stephen N, Schaid, Daniel J, PRACTICAL Consortium, Wiklund, Fredrik, Chanock, Stephen J, Easton, Douglas F, Eeles, Rosalind A, Kote-Jarai, Zsofia, Conti, David V, and Haiman, Christopher A

Subjects
PRACTICAL Consortium
Abstract

The original version of this Article contained an error in the spelling of the author Manuela Gago-Dominguez, which was incorrectly given as Manuela G. Dominguez. This has now been corrected in both the PDF and HTML versions of the Article.

Published
2019

34. Improving Guideline Adherence in Urology

Author

MacLennan, Steven, Duncan, Eilidh, Skolarus, Ted A., Roobol, Monique J., Kasivisvanathan, Veeru, Gallagher, Kevin, Gandaglia, Giorgio, Sakalis, Vasileios, Smith, Emma Jane, Plass, Karin, Ribal, Maria J., N'Dow, James, and Briganti, Alberto

Published
2022
Full Text
View/download PDF

36. Active Surveillance for Men Younger than 60 Years or with Intermediate-risk Localized Prostate Cancer. Descriptive Analyses of Clinical Practice in the Movember GAP3 Initiative

Author

Trock, Bruce, Ehdaie, Behfar, Carroll, Peter, Filson, Christopher, Logothetis, Christopher, Morgan, Todd, Klotz, Laurence, Pickles, Tom, Hyndman, Eric, Moore, Caroline, Gnanapragasam, Vincent, Van Hemelrijck, Mieke, Dasgupta, Prokar, Bangma, Chris, Roobol, Monique, Villers, Arnauld, Robert, Grégoire, Semjonow, Axel, Rannikko, Antti, Valdagni, Riccardo, Perry, Antoinette, Hugosson, Jonas, Rubio-Briones, Jose, Bjartell, Anders, Hefermehl, Lukas, Lui Shiong, Lee, Frydenberg, Mark, Stricker, Phillip, Sugimoto, Mikio, Ha Chung, Byung, van der Kwast, Theo, van der Linden, Wim, Hulsen, Tim, Ruwe, Boris, Peter van Hooft, Steyerberg, Ewout, Nieboer, Daan, Beckmann, Kerri, Denton, Brian, Hayen, Andrew, Boutros, Paul, Guo, Wei, Benfante, Nicole, Cowan, Janet, Patil, Dattatraya, Park, Lauren, Ferrante, Stephanie, Mamedov, Alexandre, LaPointe, Vincent, Crump, Trafford, Stavrinides, Vasilis, Kimberly-Duffell, Jenna, Santaolalla, Aida, Olivier, Jonathan, Rancati, Tiziana, Ahlgren, Helén, Mascarós, Juanma, Löfgren, Annica, Lehmann, Kurt, Han Lin, Catherine, Cusick, Thomas, Hirama, Hiromi, Suk Lee, Kwang, Jenster, Guido, Auvinen, Anssi, Haider, Masoom, van Bochove, Kees, Kouspou, Michelle, Paich, Kellie, Helleman, Jozien, Remmers, Sebastiaan, Hyndman, Matthew E., Moore, Caroline M., Shiong Lee, Lui, Elhage, Oussama, Morgan, Todd M., Bangma, Chris H., and Roobol, Monique J.

Published
2022
Full Text
View/download PDF

38. Updating and Integrating Core Outcome Sets for Localised, Locally Advanced, Metastatic, and Nonmetastatic Castration-resistant Prostate Cancer: An Update from the PIONEER Consortium

Author

Beyer, Katharina, Moris, Lisa, Lardas, Michael, Omar, Muhammad Imran, Healey, Jemma, Tripathee, Sheela, Gandaglia, Giorgio, Venderbos, Lionne D.F., Vradi, Eleni, van den Broeck, Thomas, Willemse, Peter-Paul, Antunes-Lopes, Tiago, Pacheco-Figueiredo, Luis, Monagas, Serenella, Esperto, Francesco, Flaherty, Stephen, Devecseri, Zsuzsanna, Lam, Thomas B.L., Williamson, Paula R., Heer, Rakesh, Smith, Emma J., Asiimwe, Alex, Huber, Johannes, Roobol, Monique J., Zong, Jihong, Mason, Malcolm, Cornford, Philip, Mottet, Nicolas, MacLennan, Sara J., N'Dow, James, Briganti, Alberto, MacLennan, Steven, and Van Hemelrijck, Mieke

Published
2022
Full Text
View/download PDF

39. Personalized Schedules for Surveillance of Low Risk Prostate Cancer Patients

Author

Tomer, Anirudh, Nieboer, Daan, Roobol, Monique J., Steyerberg, Ewout W., and Rizopoulos, Dimitris

Subjects
Statistics - Applications
Abstract

Low risk prostate cancer patients enrolled in active surveillance (AS) programs commonly undergo biopsies on a frequent basis for examination of cancer progression. AS programs employ a fixed schedule of biopsies for all patients. Such fixed and frequent schedules, may schedule unnecessary biopsies for the patients. Since biopsies have an associated risk of complications, patients do not always comply with the schedule, which increases the risk of delayed detection of cancer progression. Motivated by the world's largest AS program, Prostate Cancer Research International Active Surveillance (PRIAS), in this paper we present personalized schedules for biopsies to counter these problems. Using joint models for time to event and longitudinal data, our methods combine information from historical prostate-specific antigen (PSA) levels and repeat biopsy results of a patient, to schedule the next biopsy. We also present methods to compare personalized schedules with existing biopsy schedules., Comment: 16 pages, 5 figures, 1 table. Supplementary materials available at https://goo.gl/jpPtL8

Published
2017

40. Centralized prostatectomy with intraoperative NeuroSAFE margin assessment improves surgical margin control.

Author

Kroon, Lisa J, Remmers, Sebastiaan, Busstra, Martijn B, Gan, Melanie, Klaver, Sjoerd, Rietbergen, John B W, van der Slot, Margaretha A, Hollemans, Eva, Kweldam, Charlotte F, Bangma, Chris H, Roobol, Monique J, and van Leenders, Geert J L H

Subjects
SURGICAL margin, RADICAL prostatectomy, OPERATIVE surgery, PROSTATE cancer patients, PROSTATECTOMY, MULTIVARIABLE testing
Abstract

Aims: To investigate the surgical margin status in patients with prostate cancer who underwent robot‐assisted radical prostatectomy (RARP) with intraoperative neurovascular structure‐adjacent frozen‐section analysis (NeuroSAFE) and evaluate differences compared to patients who underwent radical prostatectomy without NeuroSAFE. Patients and Methods: Between September 2018 and January 2021, 962 patients underwent centralized RARP with NeuroSAFE. A secondary resection was performed in case of a positive surgical margin (PSM) on intraoperative frozen section (IFS) analysis to convert a PSM into a negative surgical margin (NSM). A retrospective cohort consisted of 835 patients who had undergone radical prostatectomy in a tertiary centre without NeuroSAFE between January 2000 and December 2017. We performed multivariable logistic regression to evaluate differences in risk of PSM between cohorts after controlling for clinicopathological variables. Results: Patients operated with NeuroSAFE in the centralized clinic had 29% PSM at a definitive pathological RP examination. The median cumulative length of definitive PSM was 1.1 mm (interquartile range: 0.4–3.8). Among 275 men with PSM, 136 (49%) had a cumulative length ≤1 mm and 198 (72%) ≤3 mm. After controlling for PSA, Grade group, cribriform pattern, pT‐stage, and pN‐stage, patients treated in the centralized clinic with NeuroSAFE had significantly lower odds on PSM (odds ratio [OR]: 0.70, 95% confidence interval [CI]: 0.56–0.88; P = 0.002), PSM length >1 mm (OR: 0.14, 95% CI: 0.09–0.22; P < 0.001), and >3 mm (OR: 0.21, 95% CI: 0.14–0.30; P < 0.001). Conclusion: This study provides a detailed overview of surgical margin status in a centralized RP NeuroSAFE cohort. Centralization with NeuroSAFE was associated with lower PSM rates and significantly shorter PSM cumulative lengths, indicating improved control of surgical margin status. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

45. Which men benefit from prostate cancer screening? Prostate cancer mortality by subgroup in the European Randomised Study of Screening for Prostate Cancer

Author

Pasanen, Niko, primary, Talala, Kirsi, additional, Remmers, Sebastiaan, additional, Tammela, Teuvo L. J., additional, Hugosson, Jonas, additional, Roobol, Monique J., additional, Taari, Kimmo, additional, Arnsrud Godtman, Rebecka, additional, Bangma, Chris, additional, and Auvinen, Anssi, additional

Published
2024
Full Text
View/download PDF

46. Systematic Review on the Cost Effectiveness of Prostate Cancer Screening in Europe

Author

Vynckier, Pieter, primary, Annemans, Lieven, additional, Raes, Sarah, additional, Amrouch, Cheïma, additional, Lindgren, Peter, additional, Májek, Ondřej, additional, Beyer, Katharina, additional, Leenen, Renée C.A., additional, Venderbos, Lionne D.F., additional, Denijs, Frederique, additional, van Harten, Meike J., additional, Helleman, Jozien, additional, Chloupková, Renata, additional, Briers, Erik, additional, Vasilyeva, Vera, additional, Rivas, Juan Gomez, additional, Basu, Partha, additional, Chandran, Arunah, additional, van den Bergh, Roderick C.N., additional, Collen, Sarah, additional, Van Poppel, Hein, additional, and Roobol, Monique J., additional

Published
2024
Full Text
View/download PDF

47. MP31-01 OPTIMIZING DETECTION AND PREDICTION OF PROSTATE CANCER AFTER POSITIVE MRI AND NEGATIVE BIOPSIES

Author

Zattoni, Fabio, primary, Gandaglia, Giorgio, additional, van den Bergh, Roderick, additional, Marra, Giancarlo, additional, Valerio, Massimo, additional, Olivier, Jonathan, additional, Sanzl, Ignacio Puche, additional, Rajwa, Pawel, additional, Maggi, Martina, additional, Campi, Riccardo, additional, Carletti, Filippo, additional, Amparore, Daniele, additional, De Cillis, Sabrina, additional, Guo, Hongqian, additional, Veccia, Alessandro, additional, Ditonno, Francesco, additional, Paulino Pereira, Leonor James, additional, Barletta, Francesco, additional, Leni, Riccardo, additional, Rivas, Juan Gómez, additional, Remmers, Sebastian, additional, Roobol, Monique J., additional, Antonelli, Alessandro, additional, Moro, Fabrizio Dal, additional, and Novara, Giacomo, additional

Published
2024
Full Text
View/download PDF

48. Reply to Borivoj Golijanin, Anthony Mega, and Dragan Golijanin’s Letter to the Editor re: Ivo I. de Vos, Sebastiaan Remmers, Renée Hogenhout, Monique J. Roobol, ERSPC Rotterdam Study Group. Prostate Cancer Mortality Among Elderly Men After Discontinuing Organised Screening: Long-term Results from the European Randomized Study of Screening for Prostate Cancer Rotterdam. Eur Urol 2024;85:74–81

Author

de Vos, Ivo I., primary, Remmers, Sebastiaan, additional, and Roobol, Monique J., additional

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results